Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature

[1]  S. Uehara,et al.  Cutaneous vasculitis induced by osimertinib. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  G. Fekete,et al.  Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature. , 2018, Experimental and therapeutic medicine.

[3]  M. Gekle,et al.  Role of epidermal growth factor receptor in vascular structure and function , 2014, Current opinion in nephrology and hypertension.

[4]  Sheng-Tsung Chang,et al.  Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report. , 2012, Oncology letters.

[5]  R. Hui,et al.  Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Kanekura,et al.  Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib , 2010, The Journal of dermatology.

[7]  V. Heinemann,et al.  Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Stephen W Dusza,et al.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. , 2006, Journal of the American Academy of Dermatology.